



VIA HAND DELIVERY OCTOBER 3, 2002

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of: Duan et al.

Attorney Docket No.: PF349D2

Application Serial No.: 10/028,780

Filed: December 28, 2001

Examiner: Brusca, J.

Art Unit: 1631

Title: Antibodies Directed to ELL2, A New Member of an ELL Family of RNA Polymerase II Elongation Factors

RESPONSE TO REQUIREMENT FOR STATEMENT UNDER 42 U.S.C. § 2182

ATTN: LICENSING AND REVIEW SECTION

Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Requirement mailed on September 6, 2002, Applicants respectfully assert that the above-captioned application is not "useful in the production or utilization of special nuclear material or atomic energy" within the scope of 42 U.S.C. § 2182, and thus no statement should be required.

However, assuming *arguendo* that the Requirement is proper, Applicants submit herewith the statement required by 42 U.S.C. § 2182, executed by all of the inventors of the above-captioned application. Accordingly, the Requirement and 42 U.S.C. § 2182 have been fully complied with.

No fee is believed due in connection with this submission. However, should the Patent Office determine otherwise, please charge the required fee to Deposit Account No. 08-3425.

Respectfully submitted,


Mark J. Hyman (Reg. No. 46,789)
Attorney for Applicants

Dated: October 3, 2002

RECEIVED

NOV 06 2002

Enclosure

GROUP 3600

Human Genome Sciences, Inc.
9410 Key West Avenue
Rockville, MD 20850
Telephone: (240) 314-1224

RECEIVED

OCT 07 2002

TECH CENTER 1600/2900

RECEIVED
U.S. PATENT & TRADEMARK OFFICE
OCT 14 2002
11/17/02